PT - JOURNAL ARTICLE AU - Ana Cláudia Miranda AU - Mafalda Miranda AU - Marta Pingarilho AU - Victor Pimentel AU - João Torres AU - Susana Peres AU - Teresa Baptista Alberto AU - Perpetua Gomes AU - Ana Abecasis AU - Kamal Mansinho TI - Determinants of HIV-1 late presentation in a cohort of Portuguese HIV-1 patients AID - 10.1101/2020.06.17.20133785 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.17.20133785 4099 - http://medrxiv.org/content/early/2020/06/20/2020.06.17.20133785.short 4100 - http://medrxiv.org/content/early/2020/06/20/2020.06.17.20133785.full AB - Background Undiagnosed HIV-1 patients still account for 25% of worldwide HIV patients. Studying late presenters for HIV care may help to identify characteristics of such patients.Objective The present study aims to identify factors associated with late presentation (LP) and late presentation with advanced disease (LPAD) based on a population of patients followed in a Portuguese hospital between 1984 and 2017.Methods Sociodemographic and clinical data from infected patients with HIV-1 aged 18 years and older, followed in Egas Moniz Hospital, in Portugal were collected.Results Of the 907 patients included in this study, 68.7% were males and the median age was 37 years (IQR 30-47). 459 patients (50.6%) were LP and, of these, 284 patients (61.9%) were LPAD. The LP population mostly originated from Portugal and Sub-Saharan Africa (64.4% and 28.8%; p=0.004) and the HIV exposure category mainly heterosexuals and MSM (57.0% and 24.9%; p<0.001). The stage of disease and viral load at diagnosis were significantly associated with both LP and LPAD (p<0.001). Factors associated with LP in the logistic regression included age at diagnosis lower than 30y (aOR 0.34; 0.17-0.68; p=0.002) and origin from Sub-Saharan Africa (aOR 2.24; 1.44-3.50; p<0.001).Conclusion Late presentation is a major obstacle to halt the HIV epidemic. In this population, the majority of newly diagnosed HIV-infected individuals were late presenters. Our results characterize vulnerable populations that should be frequently tested for HIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financed by FCT through the following projects: MigrantsHIV PTDC/DTP-EPI/7066/2014, BESTHOPE HIVERA: Harmonizing Integrating Vitalizing European Research on HIV/Aids, grant 249697 and GHTM- UID/Multi/04413/2013 and Gilead Genese HIVLatePresenters.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was in accordance with the declaration of Helsinki and approved by the Ethical Committee of Centro Hospitalar de Lisboa Ocidental (108/CES-2014). This database contains anonymized patients information, including demographic and clinical data from patients followed in Hospital Egas Moniz between 1984-2017.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data available